Mary Miller
Adult Health · Salem, ORNPI 1154390276
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $482 and has fallen 64.1% since, to $173 in 2024.
Across 65 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$217
- Novo Nordisk$198
- Lilly USA, LLC$112
- Bayer$109
- AbbVie$100
- E.r. Squibb & Sons, L.L.C.$95
- plus $461 from 15 others
What the payments were for
- Food & beverage$1,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $217 |
| Novo Nordisk | 10 | $198 |
| Lilly USA, LLC | 4 | $112 |
| Bayer | 6 | $109 |
| AbbVie | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $95 |
| Pfizer | 4 | $78 |
| Johnson & Johnson | 3 | $57 |
| AstraZeneca | 3 | $51 |
| Astellas Pharma US Inc | 2 | $38 |
| GSK | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Organon | 2 | $31 |
| Alfasigma USA, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
How this compares
$1,291 in reported general payments places this provider in the 75th percentile of 96 adult health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $25,288 |
| VraylarCariprazine Hcl | 12 | $18,970 |
| JanuviaSitagliptin Phosphate | 18 | $14,827 |
| JardianceEmpagliflozin | 15 | $13,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,023 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 30 | $9,100 |
| Potassium Chloride | 86 | $9,026 |
| MyrbetriqMirabegron | 15 | $7,688 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,489 |
| Acitretin | 11 | $6,948 |
| GemtesaVibegron | 12 | $6,213 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,542 |
| Pregabalin | 33 | $5,040 |
| Gabapentin | 102 | $3,284 |
| Atorvastatin Calcium | 197 | $2,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $25,28831 claims |
| AbbVieVraylar, Synthroid | $100 | $19,88325 claims |
| MerckJanuvia | $19 | $14,82718 claims |
| GSKTrelegy Ellipta | $35 | $12,02314 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $7,68815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 96 adult health providers in Oregon.
Other adult health in Salem
- Julie HinsonSalem$6K
- Katherine PorterSalem$693
- Monica ByersSalem$528
- Brandy TolliverSalem$288
- Lakshi AldredgePortland$393K
- Deborah JonesLake Oswego$44K
- Erin MyklebustPortland$14K
- Yasmine LeePortland$11K
- Terri WarrenPortland$10K
- Brenda BrewerTualatin$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.